- Todos > Quality and Safety: Medicines > Counterfeit Medicines
- Todos > Quality and Safety: Medicines > Regulatory Support
- Palabras clave > counterfeit drugs
- Palabras clave > International Medical Products Anti-Counterfeiting Taskforce - IMPACT
- Palabras clave > medicines regulatory authority (MRA)
- Palabras clave > pharmaceuticals - falsified, counterfeit
- Palabras clave > Regional Committee for Africa
- Palabras clave > substandard/spurious/falsely-labelled/falsified/counterfeit medicines (SSFFC)
- Palabras clave > Comité régional de l'Afrique
(2010; 8 pages) [French]
Considering the negative impact of substandard/spurious/falsely labelled/falsified/counterfeit medical products on public health, World Health Assembly Resolutions WHA41.16, 47.13, and 52.19 requested WHO to initiate programmes for the prevention and detection of the export, import and smuggling of such products. One of the core functions of WHO’s Essential Medicines Programme is to provide support to medicine regulatory authorities to ensure quality and safety standards of medical products. Consequently, guidelines to develop measures for combating counterfeit medicines were prepared. The guidelines provide an overview of the factors contributing to counterfeiting of medicines and include approaches to inspecting and testing suspected counterfeit medical products and providing staff training.
Furthermore, a global coalition of stakeholders, the International Medical Products Anti- Counterfeiting Taskforce (IMPACT), was established in 2006 with WHO as its Secretariat. The coalition has been active in forging international collaboration to seek solutions to this global challenge and in raising awareness of the dangers of counterfeit medical products.